Page 2 - Cell Shuttle News Today

03.08.2023 - FREDERICK, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) - TOMI Environmental Solutions, Inc. (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced a collaboration with Cellares to integrate ... Seite 1

Cell therapy offers a treatment option for some advanced blood cancers, but the manufacturing process is lengthy and complex. The biopharmaceutical industry is working on various technologies that could make manufacturing faster and more efficient, or perhaps supplant the current process altogether.

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today...

May 6, 2021 8:15am Cellares has now received a total of $100 million in funding to develop its cell therapy "factory-in-a-box." (Cellares Corporation) As cell therapies take the cancer world by storm, drugmakers are on the prowl for the latest and greatest ways to produce the complex medicines. Life sciences technology firm Cellares thinks the answer could fit in a box—a factory-in-a-box, to be precise—and the company just raised $82 million to take that work to the next level. Armed with a...

MedCity News Cellares gets $82M to make cell therapy manufacturing automated, scalable Cell therapy manufacturing is currently a manual, multi-step process that takes weeks. Startup Cellares, which is developing a system that automates the process and makes manufacturing scalable, will use the Series B financing to accelerate its work. Shares0   Talk to enough biotech industry folks and the phrase “the product is the process” is bound to come up. It refers to cell therapies, which are ma...

Cellares Raises $82M in Series B Funding Cellares Corporation, a South San Francisco, Calif.-based life sciences technology company that automates cell therapy manufacturing, secured $82m in Series B round, bringing total funding to date to $100m. The round was led by new investor Decheng Capital with participation from existing investor Eclipse Ventures and 8VC and new backer Skyviews Life Science. The company intends to use the funds to accelerate development of the Cell Shuttle. Led by F...

Cellares Raises $82M To Solve The Biggest Hurdles In Cell Therapy Manufacturing News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ --  Cellares Corporation, a life sciences technology company that automates cell therapy manufacturing, today announced it has secured $82 million in a Series B round, bringing total funding to date to $100 million. The round was led by new investor Decheng Capital and co-led by existing investor Eclipse Ven...

Cellares Adds PACT Pharma to its Early Access Partnership Program USA - English - Under the partnership, PACT Pharma will provide the company with insight into autologous NeoTCR manufacturing workflows to help identify product-market fit and secure early access to the technology for an undisclosed amount - PACT Pharma is the second organization and first industry partner to join the program following Fred Hutchinson Cancer Research Center News provided by Share this article SOUTH SAN FRANCISCO,...